Compare NEULAND LABS with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS CADILA HEALTHCARE NEULAND LABS/
CADILA HEALTHCARE
 
P/E (TTM) x 48.4 24.5 198.1% View Chart
P/BV x 3.7 4.3 85.5% View Chart
Dividend Yield % 0.1 0.8 12.2%  

Financials

 NEULAND LABS   CADILA HEALTHCARE
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
CADILA HEALTHCARE
Mar-20
NEULAND LABS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs754352 213.9%   
Low Rs247207 119.8%   
Sales per share (Unadj.) Rs594.5139.2 427.0%  
Earnings per share (Unadj.) Rs12.611.8 107.4%  
Cash flow per share (Unadj.) Rs37.018.6 199.3%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.41.3 31.9%  
Book value per share (Unadj.) Rs553.4101.4 546.0%  
Shares outstanding (eoy) m12.831,023.74 1.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.82.0 41.9%   
Avg P/E ratio x39.623.7 166.8%  
P/CF ratio (eoy) x13.515.0 89.9%  
Price / Book Value ratio x0.92.8 32.8%  
Dividend payout %15.829.8 53.2%   
Avg Mkt Cap Rs m6,421286,033 2.2%   
No. of employees `0001.313.4 9.6%   
Total wages/salary Rs m1,23624,145 5.1%   
Avg. sales/employee Rs Th5,949.410,632.7 56.0%   
Avg. wages/employee Rs Th963.81,801.2 53.5%   
Avg. net profit/employee Rs Th126.4898.5 14.1%   
INCOME DATA
Net Sales Rs m7,627142,531 5.4%  
Other income Rs m391,139 3.4%   
Total revenues Rs m7,666143,670 5.3%   
Gross profit Rs m1,01924,198 4.2%  
Depreciation Rs m3136,965 4.5%   
Interest Rs m2163,418 6.3%   
Profit before tax Rs m52914,954 3.5%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3673,198 11.5%   
Profit after tax Rs m16212,044 1.3%  
Gross profit margin %13.417.0 78.7%  
Effective tax rate %69.421.4 324.4%   
Net profit margin %2.18.5 25.1%  
BALANCE SHEET DATA
Current assets Rs m5,15287,154 5.9%   
Current liabilities Rs m3,57682,694 4.3%   
Net working cap to sales %20.73.1 660.1%  
Current ratio x1.41.1 136.7%  
Inventory Days Days10571 147.1%  
Debtors Days Days9194 96.9%  
Net fixed assets Rs m3,969133,236 3.0%   
Share capital Rs m1291,024 12.6%   
"Free" reserves Rs m6,971102,733 6.8%   
Net worth Rs m7,100103,757 6.8%   
Long term debt Rs m77432,146 2.4%   
Total assets Rs m12,310236,866 5.2%  
Interest coverage x3.55.4 64.2%   
Debt to equity ratio x0.10.3 35.2%  
Sales to assets ratio x0.60.6 103.0%   
Return on assets %3.16.5 47.0%  
Return on equity %2.311.6 19.7%  
Return on capital %9.513.7 68.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,18752,752 9.8%   
Fx outflow Rs m1,59314,504 11.0%   
Net fx Rs m3,59438,248 9.4%   
CASH FLOW
From Operations Rs m57325,054 2.3%  
From Investments Rs m-487-10,123 4.8%  
From Financial Activity Rs m-55-10,942 0.5%  
Net Cashflow Rs m333,989 0.8%  

Share Holding

Indian Promoters % 36.3 74.8 48.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 63.7 8.3 767.8%  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 11.0 579.4%  
Shareholders   12,705 44,069 28.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  ORCHID PHARMA  

Compare NEULAND LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Feb 26, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS